UNSPSC 51171721: Difenoxin hydrochloride

This classification denotes an antidiarrheal agent with the molecular formula C28H28N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VQZ63K01IW, chemically known as 4-piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, monohydrochloride but more generally known as difenoxin hydrochloride, which bears US NIH Compound Identifier 37193. European Medicines Agency schedules Difenoxin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01691MIG.

UNSPSC 51171721 Difenoxin hydrochloride is a Commodity code that represents controlled pharmaceutical substances used primarily in correctional, law enforcement, and clinical testing applications. State and local governments procure difenoxin hydrochloride—a Schedule IV opioid antidiarrheal agent—as part of broader pharmaceutical and specimen-testing programs administered by correction departments, health and human services agencies, and multistate cooperative purchasing alliances. The code reflects individual pharmaceutical SKUs within larger drug procurement frameworks rather than standalone medications, as state and local buyers acquire these products through wholesaler-managed contracts that bundle generic pharmaceuticals, OTC products, and controlled substances into coordinated supply chains serving detention facilities, community supervision programs, and healthcare systems.

Recent solicitation activity shows issuing bodies spanning state health departments, county correction supervision agencies, and multistate cooperative purchasing organizations. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services (response due July 23, 2026), seeking lab confirmation services across 25,031 annual tests with an estimated contract value of $600,000 over two years with renewal options—a procurement that drives demand for pharmaceutical testing standards and controlled-substance reference materials. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs to improve fulfillment for state pharmacy benefit programs. MMCAP (Minnesota Multistate Cooperative Purchasing Alliance), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring vendors to maintain relationships with three authorized wholesalers and comply with cGMP and DSCSA certifications. Activity clusters in Texas and Minnesota, with multistate purchasing vehicles expanding geographic reach across the Upper Midwest and South.